[Evaluation of the cardiovascular risk associated with atherosclerosis: HDL-cholesterol or apoproteins? (author's transl)].
The antiatherogenic role of HDL-cholesterol is now well established and for some years plasma HDL-cholesterol measurements have been used in the biochemical evaluation of atherosclerosis. A positive correlation has been found between low HDL-cholesterol plasma levels and high risk of cardiovascular complications. More recently, studies of the proteinic component of lipoproteins, particularly apoprotein A 1 of HDL lipoproteins and apoprotein B of LDL and VLDL lipoproteins, have shown that measurement of apoproteins is of greater help to differentiate between normal subjects and patients with coronary artery disease, irrespective of age.
D016632:Apolipoprotein A-I; D001053:Apolipoproteins / Q000097:blood*; D001055:Apolipoproteins B; D001161:Arteriosclerosis / Q000097:blood*; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D012306:Risk
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D002784:Cholesterol
Appréciation du risque cardiovasculaire lié á l'athérosclérose: HDL-cholestérol ou apoprotéines?